(Q44014358)

28 November 2017

title

Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study (English)

1 reference

28 November 2017

1 reference

1 reference

2

1 reference

28 November 2017

4

1 reference

28 November 2017

9

1 reference

28 November 2017

Teresa Santantonio

1

1 reference

28 November 2017

Emanuele Sinisi

3

1 reference

28 November 2017

Maria Insalata

5

1 reference

28 November 2017

Angela Guastadisegni

6

1 reference

28 November 2017

Domenico Facciorusso

7

1 reference

28 November 2017

Eleonora Gravinese

8

1 reference

28 November 2017

Giuseppe Pastore

10

1 reference

28 November 2017

publication date

1 June 2002

1 reference

28 November 2017

published in

Journal of Hepatology

1 reference

28 November 2017

volume

36

1 reference

28 November 2017

issue

6

1 reference

28 November 2017

page(s)

799-804

1 reference

A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

28 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Lamivudine as initial treatment for chronic hepatitis B in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Long-term therapy of chronic hepatitis B with lamivudine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Dynamics of hepatitis B virus infection in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Viral dynamics in hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Effect of interferon alpha on hepatitis B virus replication and gene expression in transiently transfected human hepatoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

In vitro evaluation of combination therapies against hepatitis B virus replication

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2802%2900056-9

7 January 2021

10.1016/S0168-8278(02)00056-9

Identifiers

DOI

1 reference

28 November 2017

1 reference